Genmab’s Q1 Surge Masks a Critical Phase 3 Miss

Forward-Looking Analysis

Analysts project Genmab will generate approximately $6.2 billion in revenue and $1.6 billion in earnings by 2029, requiring 16.8% annual revenue growth and an $821 million to $1.6 billion earnings increase. Current baseline forecasts assume revenue of $7.3 billion and earnings of $2.3 billion by 2029 under optimistic scenarios. Truist Financial analyst Gregory Renza maintained a Buy rating on Genmab with a $38.00 price target, representing a 35.1% upside from the recent close of $28.64. TD Cowen upgraded the stock to Buy with a $43.00 price target. The analyst consensus for Genmab is Strong Buy. Simply Wall St analysis suggests a DKK2392 fair value, indicating a 29% upside to the current price. These estimates rely on historical data and analyst forecasts, projecting durable cash flows despite clinical setbacks.

Historical Performance Review

Genmab reported strong results for 2026Q1, generating $896.00 million in revenue and $53.00 million in net income. Earnings per share stood at $0.84, supported by a gross profit of $831.00 million. These figures demonstrate robust operational efficiency and solid top-line growth, providing a stable financial foundation heading into the Q2 report. The high gross margin indicates effective cost management and strong demand for its core oncology products.

Additional News

In July 2026, Genmab and AbbVie clarified that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed to achieve statistical significance in overall survival, its sole primary endpoint in the US. This setback highlights region-specific trial complexities, though the European Commission recently approved TEPKINLY (epcoritamab) plus R2 for relapsed or refractory follicular lymphoma. This approval underscores epcoritamab’s value beyond the DLBCL-1 miss, supporting expanded labeled uses across B-cell malignancies. While the US overall-survival miss is a specific setback, it does not alter Genmab’s near-term financial guidance. Investors await detailed peer-reviewed data to assess the broader clinical profile. The company’s narrative remains focused on translating antibody platforms into diversified cash flows, despite the risk of pipeline execution missteps affecting long-term earnings resilience.

Summary & Outlook

Genmab demonstrates solid financial health, evidenced by strong Q1 margins and revenue. However, the recent EPCORE DLBCL-1 trial failure introduces significant near-term risk, potentially impacting sentiment despite no change to financial guidance. Growth catalysts include EU approvals for epcoritamab in follicular lymphoma and steady pipeline execution. Conversely, dependence on a focused oncology pipeline poses execution risks. Analysts remain bullish with a Strong Buy consensus and substantial upside targets. We maintain a neutral-to-bearish stance for Q2 due to clinical uncertainty, though long-term fundamentals remain intact if pipeline milestones are met.